191 related articles for article (PubMed ID: 26631267)
1. SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm.
Hamblett KJ; Jacob AP; Gurgel JL; Tometsko ME; Rock BM; Patel SK; Milburn RR; Siu S; Ragan SP; Rock DA; Borths CJ; O'Neill JW; Chang WS; Weidner MF; Bio MM; Quon KC; Fanslow WC
Cancer Res; 2015 Dec; 75(24):5329-40. PubMed ID: 26631267
[TBL] [Abstract][Full Text] [Related]
2. SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads.
Kinneer K; Meekin J; Tiberghien AC; Tai YT; Phipps S; Kiefer CM; Rebelatto MC; Dimasi N; Moriarty A; Papadopoulos KP; Sridhar S; Gregson SJ; Wick MJ; Masterson L; Anderson KC; Herbst R; Howard PW; Tice DA
Clin Cancer Res; 2018 Dec; 24(24):6570-6582. PubMed ID: 30131388
[TBL] [Abstract][Full Text] [Related]
3. SLC46A3 is a lysosomal proton-coupled steroid conjugate and bile acid transporter involved in transport of active catabolites of T-DM1.
Tomabechi R; Kishimoto H; Sato T; Saito N; Kiyomiya K; Takada T; Higuchi K; Shirasaka Y; Inoue K
PNAS Nexus; 2022 Jul; 1(3):pgac063. PubMed ID: 36741448
[TBL] [Abstract][Full Text] [Related]
4. Sensitive ELISA Method for the Measurement of Catabolites of Antibody-Drug Conjugates (ADCs) in Target Cancer Cells.
Salomon PL; Singh R
Mol Pharm; 2015 Jun; 12(6):1752-61. PubMed ID: 25738394
[TBL] [Abstract][Full Text] [Related]
5. Identification of 5-Carboxyfluorescein as a Probe Substrate of SLC46A3 and Its Application in a Fluorescence-Based In Vitro Assay Evaluating the Interaction with SLC46A3.
Tomabechi R; Miyasato M; Sato T; Takada T; Higuchi K; Kishimoto H; Shirasaka Y; Inoue K
Mol Pharm; 2023 Jan; 20(1):491-499. PubMed ID: 36458938
[TBL] [Abstract][Full Text] [Related]
6. Macrolide and Ketolide Antibiotics Inhibit the Cytotoxic Effect of Trastuzumab Emtansine in HER2-Positive Breast Cancer Cells: Implication of a Potential Drug-ADC Interaction in Cancer Chemotherapy.
Kiyomiya K; Tomabechi R; Saito N; Watai K; Takada T; Shirasaka Y; Kishimoto H; Higuchi K; Inoue K
Mol Pharm; 2023 Dec; 20(12):6130-6139. PubMed ID: 37971309
[TBL] [Abstract][Full Text] [Related]
7. Detection and Characterization of In Vitro Payload-Containing Catabolites of Noncleavable Antibody-Drug Conjugates by High-Resolution Mass Spectrometry and Multiple Data Mining Tools.
Cai T; Shi L; Guo H; Li R; Cao W; Shen L; Zhu M; Tao Y
Drug Metab Dispos; 2023 May; 51(5):591-598. PubMed ID: 36707253
[TBL] [Abstract][Full Text] [Related]
8. A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells.
Singh R; Setiady YY; Ponte J; Kovtun YV; Lai KC; Hong EE; Fishkin N; Dong L; Jones GE; Coccia JA; Lanieri L; Veale K; Costoplus JA; Skaletskaya A; Gabriel R; Salomon P; Wu R; Qiu Q; Erickson HK; Lambert JM; Chari RV; Widdison WC
Mol Cancer Ther; 2016 Jun; 15(6):1311-20. PubMed ID: 27197308
[TBL] [Abstract][Full Text] [Related]
9. Altering Antibody-Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability.
Hamblett KJ; Le T; Rock BM; Rock DA; Siu S; Huard JN; Conner KP; Milburn RR; O'Neill JW; Tometsko ME; Fanslow WC
Mol Pharm; 2016 Jul; 13(7):2387-96. PubMed ID: 27248573
[TBL] [Abstract][Full Text] [Related]
10. CRISPR-Cas9 screens identify regulators of antibody-drug conjugate toxicity.
Tsui CK; Barfield RM; Fischer CR; Morgens DW; Li A; Smith BAH; Gray MA; Bertozzi CR; Rabuka D; Bassik MC
Nat Chem Biol; 2019 Oct; 15(10):949-958. PubMed ID: 31451760
[TBL] [Abstract][Full Text] [Related]
11. Optimizing Lysosomal Activation of Antibody-Drug Conjugates (ADCs) by Incorporation of Novel Cleavable Dipeptide Linkers.
Salomon PL; Reid EE; Archer KE; Harris L; Maloney EK; Wilhelm AJ; Miller ML; Chari RVJ; Keating TA; Singh R
Mol Pharm; 2019 Dec; 16(12):4817-4825. PubMed ID: 31609629
[TBL] [Abstract][Full Text] [Related]
12. Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates.
Ponte JF; Sun X; Yoder NC; Fishkin N; Laleau R; Coccia J; Lanieri L; Bogalhas M; Wang L; Wilhelm S; Widdison W; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2016 Jul; 27(7):1588-98. PubMed ID: 27174129
[TBL] [Abstract][Full Text] [Related]
13. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R
Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424
[TBL] [Abstract][Full Text] [Related]
14. Development and evaluation of β-galactosidase-sensitive antibody-drug conjugates.
Kolodych S; Michel C; Delacroix S; Koniev O; Ehkirch A; Eberova J; Cianférani S; Renoux B; Krezel W; Poinot P; Muller CD; Papot S; Wagner A
Eur J Med Chem; 2017 Dec; 142():376-382. PubMed ID: 28818506
[TBL] [Abstract][Full Text] [Related]
15. Exploring the effects of linker composition on site-specifically modified antibody-drug conjugates.
Albers AE; Garofalo AW; Drake PM; Kudirka R; de Hart GW; Barfield RM; Baker J; Banas S; Rabuka D
Eur J Med Chem; 2014 Dec; 88():3-9. PubMed ID: 25176286
[TBL] [Abstract][Full Text] [Related]
16. Intracellular Catabolism of an Antibody Drug Conjugate with a Noncleavable Linker.
Rock BM; Tometsko ME; Patel SK; Hamblett KJ; Fanslow WC; Rock DA
Drug Metab Dispos; 2015 Sep; 43(9):1341-4. PubMed ID: 26101225
[TBL] [Abstract][Full Text] [Related]
17. Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering.
Pillow TH; Tien J; Parsons-Reponte KL; Bhakta S; Li H; Staben LR; Li G; Chuh J; Fourie-O'Donohue A; Darwish M; Yip V; Liu L; Leipold DD; Su D; Wu E; Spencer SD; Shen BQ; Xu K; Kozak KR; Raab H; Vandlen R; Lewis Phillips GD; Scheller RH; Polakis P; Sliwkowski MX; Flygare JA; Junutula JR
J Med Chem; 2014 Oct; 57(19):7890-9. PubMed ID: 25191794
[TBL] [Abstract][Full Text] [Related]
18. Highly Potent, Anthracycline-based Antibody-Drug Conjugates Generated by Enzymatic, Site-specific Conjugation.
Stefan N; Gébleux R; Waldmeier L; Hell T; Escher M; Wolter FI; Grawunder U; Beerli RR
Mol Cancer Ther; 2017 May; 16(5):879-892. PubMed ID: 28258164
[TBL] [Abstract][Full Text] [Related]
19. Improved Lysosomal Trafficking Can Modulate the Potency of Antibody Drug Conjugates.
DeVay RM; Delaria K; Zhu G; Holz C; Foletti D; Sutton J; Bolton G; Dushin R; Bee C; Pons J; Rajpal A; Liang H; Shelton D; Liu SH; Strop P
Bioconjug Chem; 2017 Apr; 28(4):1102-1114. PubMed ID: 28151644
[TBL] [Abstract][Full Text] [Related]
20. New Insights in Tissue Distribution, Metabolism, and Excretion of [3H]-Labeled Antibody Maytansinoid Conjugates in Female Tumor-Bearing Nude Rats.
Walles M; Rudolph B; Wolf T; Bourgailh J; Suetterlin M; Moenius T; Peraus G; Heudi O; Elbast W; Lanshoeft C; Bilic S
Drug Metab Dispos; 2016 Jul; 44(7):897-910. PubMed ID: 27122302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]